NCT03203876View on ClinicalTrials.gov

A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 14, 2017

Primary Completion Date

August 6, 2020

Study Completion Date

August 6, 2020

Conditions
Advanced Cancer
Interventions
BIOLOGICAL

Lirilumab

Specified dose on specified days

BIOLOGICAL

Nivolumab

Specified dose on specified days

BIOLOGICAL

Ipilimumab

Specified dose on specified days

Trial Locations (2)

2778577

Local Institution, Kashiwa-shi

6500017

Local Institution, Kobe

Sponsors
All Listed Sponsors
collaborator

Ono Pharmaceutical Co. Ltd

INDUSTRY

lead

Bristol-Myers Squibb

INDUSTRY

NCT03203876 - A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter